MCA (mucin-like carcinoma-associated antigen) is an acid soluble glycoprotein which shows a mucinous nature with an apparent molecular weight of 350 kD, produced by oestrogendependent and oestrogenindependent mammary carcinoma cells[ 11. lmmunohistochemical techniques used by Zenklusen et a1. [2] demonstrated its presence at elevated concentrations in neoplastic breast tissues, independently from histology and the presence or absence of steroid receptors. It also has been detected in non-neoplastic breast tissue and in other epithelial tumors, although at lower concentrations [3] . Immunohistochemical studies showed that MCA is expressed on mucinous epithelial surfaces and in mucinous secretions of normal and cancerous breast tissue. It has been shown that in breast neoplastic cells MCA is hstributed throughout the cytoplasm, while in normal breast tissue, the positivity is always limited to the secretion underlymg the glandular lumina [l] . MCA localization has also been demonstrated in other glandular epithelial tissues (particularly mucinous epithelia) even if staining intensity and rate of cell positivity was poorer than in neoplastic breast cells [4] .
Furthermore, elevated MCA levels have been demonstrated in the sera of breast cancer patients and the MCA has recently been studied as a useful serological marker for breast cancer [S] . MCA is not elevated in smokers (in contrast to CEA) nor in cases of benign breast tumors, such as papillomas and fibrocytic disease [6] . CA 125 (cancer antigen 125) is an antigenic determinant on a high-molecular-weight glycoprotein recognized by a monoclonal antibody (OC 125) which was raised using an ovarian cancer cell line as an immunogen. CA 125 determinant is a normal product of endometrial tissue. In adult tissue the monoclonal antibody OC 125 reacted with the epithelium of the fallopian tube, endometrium, and endocervix and has also been found expressed in the apocrine sweat gland and the mammary glands. CA 125 was originally developed for detection of ovarian cancer, but has also been shown to be positive in other adenocarcinomas, such as breast cancer [7] . The CA 19.9 (carbohydrate antigen 19.9) in tissues exists primarily as an epitope present on a glycolipid, sialo-lacto-N fucopentaose I1 ganglioside, but in serum, the CA 19.9 antigen is associated with a mucin [8] .
This study was undertaken in the Department of Biochemistry, at Dokuz Eyliil University Medical Faculty, between June 1993 and January 1995; a total of 108 patients with primary breast cancer (age range 30-70), 40 patients with benign breast disease (BBD) (aged 18-53), and 26 healthy women (aged 18-52) were included in the study. The 40 benign lesions, all histologically confirmed, were: 18 fibroadenomas, 10 fibrocystic diseases, 4 hyperplasia, 2 papilloma, 2 granulomatosis mastite and 4 other non-malignant pathologies. Patients with malignant pathology and histological confirmation according to the WHO classification were staged using the TNM system of UICC (UICC. TNM classification of malignant tumors. Geneva:MH Harmer, 1979). The tumor markers MCA, CA 19 9 and CA 125 were determined by two-side solid phase enzyme immunoassay (EIA) (Hoffmann-La Roche, Basel, Switzerland) in the sera of a total of 174 individuals. This involved a two-side solid phase enzyme immunoassay-sandwich e v e immunoassay-in which the Same antibody is used as the capture and the indmtor antibody, because the recognized epitope is presented in multiple locations on the antigen. All measurements were done by the <Cobas> EIA photometer, automatically. The coefficients of variation of the assays were determined to be as follows: the intra-assay coefficient of variation (CV) were 2.5 % for MCA,3.4 % for CA 19.9, and 5.6 % for CA 125; the between-assay coefficients of variations ranged between 3.5 % and 9.6 'YO for MCA, 4.2 ' Yo and 11.5 'YO for CA 19.9, and 3.8 ' YO and 5.4 % for CA 125.and depending on the concentration of the control sera.
The obtained tumor marker conciritrations were statistically analyzed using Student's t test, Wilcoxon test and, Mann-Whitney test, accepting a "p" value below 5 % (p< 0.05) as significant. The diagnostic parameters were evaluated using the following formulas: (TP= number of true positive values; TN= number of true negative d u e s ; FP= number of false positive values; FN= number of false negative values): Sensitivity (%) = (TPfI'P + FN) x 100; Specificity (%) = (TNRN + FP) x 100. Serum MCA, CA 125 and CA 19.9 levels in cancer patients, BBD, and healthy controls are summarized in Table 1 In Table 2 , the diagnostic parameters (sensitivity and specificity) are The data obtained in our study have revealed clearly that of the three tumor markers studied, serum MCA is significantly higher in the malignant breast cases than both the benign cases and the healthy icdividuals; th~s finding is in keeping with other published data for MCA(2-5,9) and CA 125 (7). We have found no literature data on the status of CA 19.9 in breast carcinoma. An interesting results which arises from the diagnostic evaluation of these data is that, a combination of these three markers elevate the sensitivity and specificity parameters to 90 % and 98 %, respectively. These values are d e f~t e l y more satisfactory
